COMPANY PROFILE

Shukun Technology

Explore full profile

A Chinese AI medical company that focuses on developing diagnostics systems for chronic diseases

Tongzhou District, ChinaFounded 2017Health Tech & Medtech

Valuation $1–2.5B Last recorded · 2021

Revenue $1–10M Latest reported FY

Headcount <100 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About Shukun Technology

Established in 2017, Shukun Technology is a medical artificial intelligence company headquartered in Beijing, China, specializing in the application of AI to medical imaging. The company was co-founded by the husband-and-wife team of Victor Mao (Mao Xinsheng), who serves as Chairman, and Anne Ma (Ma Chun'e), who is the CEO. Both founders leverage extensive backgrounds in technology from their previous roles at IBM. Victor Mao holds a master's degree in computer science from Peking University and has deep experience in cloud computing, big data, and AI, having been the CTO of IBM China's R&D Center. Anne Ma earned a master's in computer networking from Northwestern Polytechnic University and was a research and development manager at IBM's Emerging Technology Research Institute, receiving accolades for her technical contributions. Their combined expertise in information technology and AI forms the foundation of Shukun's mission to address the growing disparity between the volume of medical imaging examinations and the limited number of available radiologists.

Read full description

Shukun Technology develops and provides an AI-powered platform called "Digital Doctor" (or "DigitalDoc"), designed to assist clinicians in disease screening, diagnosis, and treatment planning by analyzing medical imaging data. The platform can significantly accelerate diagnostic efficiency, in some cases by up to tenfold. The company operates on a B2B model, serving hospitals and health check-up centers. Its revenue is generated through a subscription-based model for its software and by direct sales. Shukun's product portfolio is extensive, covering critical therapeutic areas such as the heart, brain, chest, abdomen, and musculoskeletal system, which addresses a wide spectrum of prevalent and serious diseases. Specific products include AI-assisted diagnostic tools for coronary CT angiography (CTA), cerebral CTA, pneumonia, and lung nodule detection. The company has achieved significant regulatory milestones, including NMPA Class III certificates in China for its coronary CTA and pneumonia products, as well as four CE marks.

The company's solutions have been adopted by over 3,000 hospitals and 1,000 health check-up centers, with a strong presence in China's top-tier medical institutions. Since its inception, Shukun Technology has secured substantial funding through multiple financing rounds, including a notable Series D in August 2021, attracting investment from prominent firms like Sequoia Capital China, Goldman Sachs Asset Management, and Huagai Capital. This financial backing supports ongoing research and development for its "digital human body" platform and the expansion of its product matrix. The company is also expanding its global footprint, entering into strategic partnerships, such as an alliance with Clairvo Technologies to introduce its cardiac AI products to the Japanese market.

Source: Dealroom company data